Fund from Tulane College, NIH Grant EY021862, a profession progress award with the Research to circumvent Blindness basis, and also a Vibrant Concentration Foundation Award in Agerelated Macular Degeneration.Br J Ophthalmol. Writer manuscript; available in PMC 2016 July fourteen.Hanus et al.PageBibliography1. Wong WL, Su X, Li X, et al. International prevalence of agerelated macular degeneration and disease stress projection for 2020 and 2040: a systematic evaluation and metaanalysis. The Lancet. World 1609402-14-3 Purity health and fitness. 2014; two(two):e106 116. [published On-line Very first: Epub Date]. [PubMed: 25104651] two. Gordois A, Pezzullo L, Cutler H. The global Financial Cost of Visible Impairment: AMD Alliance Intercontinental. 2010 3. Jager RD, Mieler WF, Miller JW. Agerelated macular degeneration. N Engl J Med. 2008; 358(24): 2606617. [published On line To start with: Epub Date]. [PubMed: 18550876] four. de Jong PT. Agerelated macular degeneration. N Engl J Med. 2006; 355(14):1474485. [published Online 1st: Epub Date]. [PubMed: 17021323] 5. Holz FG, Strauss EC, SchmitzValckenberg S, van Lookeren Campagne M. Geographic atrophy: medical characteristics and prospective therapeutic techniques. Ophthalmology. 2014; 121(5):1079091. [published Online Very first: Epub Date]. [PubMed: 24433969] 6. Patel HR, Eichenbaum D. Geographic atrophy: scientific impact and rising remedies. Ophthalmic medical procedures, lasers imaging retina. 2015; 46(1):eighty three. [published On line Initially: Epub Date]. 7. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular agerelated macular degeneration. N Engl J Med. 2006; 355(14):1432444. [published On-line Initial: Epub Date]. [PubMed: 17021319] 8. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular agerelated macular degeneration. N Engl J Med. 2006; 355(fourteen):1419431. [published Online 1st: Epub Date]. [PubMed: 17021318] 9. Zampros I, Praidou A, Brazitikos P, Ekonomidis P, Androudi S. Antivascular endothelial advancement factor agents for neovascular agerelated macular degeneration. Journal of ophthalmology. 2012; 2012:319728. [published On-line First: Epub Date]. [PubMed: 22174998] ten. AgeRelated Eye Disease Review 2 Analysis G. Lutein zeaxanthin and omega3 fatty acids for agerelated macular degeneration: the AgeRelated Eye Ailment Research 2 (AREDS2) randomized medical demo. JAMA. 2013; 309(19):2005015. [published On-line Initial: Epub Date]. [PubMed: 23644932] 11. AgeRelated Eye Disorder Research Exploration G. A randomized, placebocontrolled, scientific trial of highdose supplementation with natural vitamins C and E, beta carotene, and zinc for agerelated macular degeneration and vision decline: AREDS report no. 8. Archives of ophthalmology. 2001; 119(ten): 1417436. [PubMed: 11594942] 12. Beatty S, Koh H, Phil M, Henson D, Boulton M. The function of oxidative stress inside the pathogenesis of agerelated macular degeneration. Surv Ophthalmol. 2000; 45(two):11534. [published On-line Initially: Epub Date]. [PubMed: 11033038] thirteen. Khandhadia S, Lotery A. Oxidation and agerelated macular degeneration: insights from molecular biology. Pro reviews in molecular medicine. 2010; 12:e34. [published On the net Initially: Epub Date]. [PubMed: 20959033] fourteen. Hanus J, Zhang H, Wang Z, Liu Q, Zhou Q, Wang S. Induction of necrotic cell death by oxidative pressure Pub Releases ID:http://results.eurekalert.org/pub_releases/2014-09/esfm-aip092614.php in retinal pigment epithelial cells. Mobile Loss of life Dis. 2013; four:e965. [published Online To start with: Epub Date]. [PubMed: 24336085] fifteen. Hashizume K, Hirasawa M, Imamura Y, et al. Retinal dysfunction and progressive retinal cell demise in SOD1deficient mice. Am J Pathol. 2008; 172(five.